Clinic
East Tennessee Children's Hospital Association INC.
East Tennessee Children's Hospital Association INC. was paid $88.61M by Medicaid between Jan 2018 and Dec 2024, across 219 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoEAST TENNESSEE CHILDREN'S HOSPITAL ASSOCIATION INC.
KNOXVILLE, TN 37916
KNOXVILLE, TN 37916
33aNPI1760476659assigned 09/07/2005
33bProvider typeRehabilitation Clinic/Center
28Total paid$88.61M
24GClaims1,158,010
24DCodes billed219
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Clinic/Center providers in Tennessee
Rank by total paid#1 of 27
Median peer was paid$46K
This provider vs. median1,935×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ROSENDAHL, ANDREW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 155,288 | $11.15M | |
| 2019 | 155,119 | $11.70M | |
| 2020 | 107,608 | $8.51M | |
| 2021 | 165,522 | $13.15M | |
| 2022 | 183,592 | $13.60M | |
| 2023 | 200,719 | $15.38M | |
| 2024incomplete | 190,162 | $15.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 129,862 | 125,040 | $27.22M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 48,668 | 46,819 | $13.30M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 7.6% | 8,798 | 7,996 | $6.76M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.7% | 33,874 | 32,805 | $5.08M |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.9% | 4,847 | 4,643 | $3.43M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.5% | 4,866 | 4,475 | $2.22M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.3% | 1,447 | 1,373 | $2.04M |
| G0378 | Hospital observation service, per hour | 2.3% | 3,327 | 2,977 | $2.00M |
| 95782 | 2.2% | 2,596 | 2,290 | $1.99M | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.9% | 36,466 | 34,601 | $1.65M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.8% | 11,905 | 9,162 | $1.63M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 9,291 | 7,181 | $1.55M |
207 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 20,305 | $1.48M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.4% | 1,019 | $1.20M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.2% | 3,523 | $1.09M |
| 99285 | Emergency room visit (most serious) | 1.2% | 2,745 | $1.05M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.0% | 4,115 | $927K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.0% | 13,197 | $923K |
| G0175 | Scheduled interdisciplinary team conference (minimum of three exclusive of patient care nursing staff) with patient present | <1% | 4,714 | $834K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 16,594 | $804K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 9,544 | $602K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,362 | $579K |
| 93325 | <1% | 12,599 | $533K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,821 | $518K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,377 | $515K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 18,693 | $487K |
| 93320 | <1% | 11,917 | $412K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 32,906 | $375K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,545 | $371K |
| 36415 | Collection of venous blood by venipuncture | <1% | 120,930 | $355K |
| 95819 | <1% | 2,885 | $326K | |
| 81001 | <1% | 37,193 | $321K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,263 | $312K |
| 94060 | <1% | 7,745 | $312K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 52,390 | $281K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 4,462 | $273K |
| A0225 | Ambulance service, neonatal transport, base rate, emergency transport, one way | <1% | 807 | $257K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 9,317 | $245K |
| 74019 | <1% | 23,141 | $232K | |
| 87400 | <1% | 34,776 | $207K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,710 | $205K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 39,470 | $191K |
| 94010 | <1% | 7,720 | $176K | |
| 72146 | <1% | 530 | $165K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 519 | $161K |
| 72141 | <1% | 543 | $156K | |
| 80053 | Comprehensive metabolic panel | <1% | 22,481 | $148K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 23,130 | $145K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 21,118 | $120K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 309 | $120K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,226 | $107K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,948 | $105K |
| 76770 | <1% | 1,464 | $103K | |
| 95957 | <1% | 1,501 | $90K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,126 | $89K |
| 87807 | <1% | 10,491 | $88K | |
| 87581 | <1% | 4,126 | $87K | |
| 87486 | <1% | 4,116 | $87K | |
| 94760 | <1% | 19,678 | $83K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,133 | $82K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,855 | $70K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,632 | $64K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,103 | $61K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 435 | $60K |
| 93000 | <1% | 3,382 | $52K | |
| 97161 | <1% | 494 | $49K | |
| 97803 | <1% | 1,786 | $48K | |
| 99205 | Prolong outpt/office vis | <1% | 654 | $47K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,183 | $47K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,235 | $47K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 5,267 | $47K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,195 | $44K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 546 | $43K |
| 86140 | <1% | 13,666 | $41K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,712 | $39K |
| 87088 | <1% | 8,805 | $39K | |
| 74018 | <1% | 1,860 | $35K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 82 | $30K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,759 | $29K |
| 84439 | <1% | 5,012 | $26K | |
| 82570 | <1% | 4,991 | $26K | |
| 94664 | <1% | 2,322 | $23K | |
| 85045 | <1% | 1,311 | $23K | |
| 80061 | Lipid panel | <1% | 2,597 | $21K |
| 78227 | <1% | 62 | $21K | |
| 77072 | <1% | 753 | $20K | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 771 | $18K |
| 97802 | <1% | 554 | $17K | |
| 82043 | <1% | 389 | $17K | |
| 96156 | <1% | 224 | $16K | |
| 81025 | <1% | 4,375 | $15K | |
| 83525 | <1% | 703 | $12K | |
| 87632 | <1% | 107 | $12K | |
| 85730 | <1% | 2,196 | $12K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 666 | $11K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 438 | $10K |
| 83690 | <1% | 995 | $10K | |
| 92526 | <1% | 174 | $9K | |
| 94762 | <1% | 1,664 | $9K | |
| 83655 | <1% | 671 | $8K | |
| 85610 | <1% | 2,396 | $7K | |
| 95812 | <1% | 58 | $6K | |
| 99243 | <1% | 101 | $6K | |
| 82340 | <1% | 1,572 | $6K | |
| 82553 | <1% | 122 | $6K | |
| 85652 | <1% | 1,254 | $6K | |
| 95811 | <1% | 13 | $6K | |
| 97165 | <1% | 60 | $6K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 22,594 | $5K |
| 74240 | <1% | 90 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 293 | $5K |
| 86308 | <1% | 698 | $5K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 38 | $4K |
| 84156 | <1% | 2,891 | $4K | |
| 87040 | <1% | 492 | $4K | |
| 87070 | <1% | 788 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 143 | $4K |
| 82657 | <1% | 4,706 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 143 | $4K |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 62 | $4K |
| 82784 | <1% | 203 | $4K | |
| 86003 | <1% | 201 | $4K | |
| 82785 | <1% | 218 | $3K | |
| 82272 | <1% | 786 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 64 | $3K |
| 95251 | <1% | 75 | $3K | |
| 84100 | <1% | 337 | $2K | |
| 83001 | <1% | 81 | $2K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 24 | $2K |
| 76857 | <1% | 56 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 203 | $2K |
| 54150 | <1% | 14 | $2K | |
| 81003 | <1% | 1,551 | $2K | |
| 84146 | <1% | 70 | $2K | |
| 75809 | <1% | 65 | $2K | |
| 85027 | <1% | 1,201 | $2K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 63 | $2K |
| 86258 | <1% | 115 | $2K | |
| 86364 | <1% | 115 | $2K | |
| 84550 | <1% | 264 | $2K | |
| 82150 | <1% | 561 | $2K | |
| A0425 | Ground mileage, per statute mile | <1% | 16 | $2K |
| 83516 | <1% | 59 | $2K | |
| 96040 | <1% | 43 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,378 | $1K |
| 82550 | <1% | 147 | $1K | |
| 80069 | <1% | 171 | $1K | |
| 87081 | <1% | 124 | $1K | |
| 83002 | <1% | 37 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 35 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,196 | $968.28 |
| 89220 | <1% | 111 | $960.92 | |
| 86769 | <1% | 26 | $926.88 | |
| 74455 | <1% | 13 | $926.38 | |
| 96167 | <1% | 14 | $856.66 | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 30 | $833.38 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 14 | $813.08 |
| 83013 | <1% | 14 | $741.04 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 57 | $680.24 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 234 | $657.73 |
| 93225 | <1% | 40 | $628.62 | |
| 83993 | <1% | 43 | $611.08 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 113 | $532.34 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,032 | $496.93 |
| 82247 | <1% | 70 | $475.68 | |
| 84484 | <1% | 66 | $469.48 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,333 | $468.17 |
| 82248 | <1% | 73 | $433.18 | |
| 83880 | <1% | 26 | $431.55 | |
| 71045 | Radiologic examination, chest; single view | <1% | 86 | $430.58 |
| 82728 | <1% | 107 | $402.72 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 957 | $390.65 |
| 82803 | <1% | 12 | $312.90 | |
| 83630 | <1% | 28 | $306.72 | |
| 86256 | <1% | 30 | $305.23 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 12,254 | $305.12 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15 | $276.31 |
| 87186 | <1% | 29 | $256.41 | |
| 82962 | <1% | 58 | $241.86 | |
| 81015 | <1% | 205 | $178.05 | |
| 82977 | <1% | 152 | $175.81 | |
| 51600 | <1% | 13 | $167.60 | |
| 86255 | <1% | 17 | $163.83 | |
| 87045 | <1% | 12 | $132.42 | |
| 91035 | <1% | 14 | $131.50 | |
| 84030 | <1% | 151 | $123.12 | |
| 51701 | <1% | 601 | $123.00 | |
| 83550 | <1% | 41 | $104.53 | |
| 86038 | <1% | 60 | $94.56 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,224 | $92.42 |
| 76000 | <1% | 679 | $86.11 | |
| 88342 | <1% | 463 | $73.56 | |
| 83735 | <1% | 24 | $71.82 | |
| 83615 | <1% | 14 | $67.39 | |
| 87427 | <1% | 12 | $64.48 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 297 | $62.82 |
| 83540 | <1% | 27 | $61.53 | |
| 87210 | <1% | 12 | $61.50 | |
| 96160 | <1% | 14 | $47.74 | |
| 87046 | <1% | 12 | $35.43 | |
| 86225 | <1% | 12 | $26.85 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,384 | $16.97 |
| 86060 | <1% | 13 | $14.28 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 435 | $11.93 |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 15 | $6.30 |
| J3490 | Unclassified drugs | <1% | 229 | $4.75 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 29 | $1.99 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 309 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 400 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 140 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 12 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 33 | $0.00 |
| 99188 | 0% | 827 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 285 | $0.00 |
| A4362 | Skin barrier; solid, 4 x 4 or equivalent; each | 0% | 45 | $0.00 |
| J0290 | Injection, ampicillin sodium, 500 mg | 0% | 87 | $0.00 |
| 84145 | 0% | 15 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROSENDAHL, ANDREW (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.